Vice President, Real World Evidence, Medical Affairs
Novavax, Inc.
Disclosure(s): Novavax, Inc.: employee, Stocks/Bonds (Public Company)
Matthew is Vice President, RWE at Novavax (a biotech company committed to help address serious infectious diseases). He has over 20 years of industry experience in pharma and bio, with the majority of his experience in Global and U.S. leadership roles in health economics and outcomes research.
Matthew has also held various roles at Eli Lilly, MedImmune/AZ, GSK, and Takeda, leading evidence generation across a wide portfolio as well as roles in market access public policy, quality measures, and innovative financing policies.
Matthew completed his studies at Rutgers University and The University of Alabama at Birmingham.